De pil van Pharvaris werkt overigens bij alle typen van HAE. Dus is een sterke concurrent voor Pharming.
Multiple therapies are available, acting at different points in the bradykinin-forming cascade. Only one approved therapy, icatibant, acts directly at the bradykinin B2 receptor to treat all types of HAE by inhibiting bradykinin interaction with its bradykinin B2 receptor target, and hence by putting a halt to bradykinin-mediated signaling.
All current therapies, including icatibant, are limited by invasive routes of drug administration (injection or infusion), inconvenient dosing regimens, or undesired side effects. Surveys of patients with HAE overwhelmingly show that they seek additional treatment options.
A first-in-class, oral small-molecule antagonist of the bradykinin B2 receptor may provide an effective and more convenient way to manage HAE and improve quality of life.